Recently, the Asia-Pacific Economic Cooperation (APEC) meeting was held in Gyeongju, South Korea. Suzhou Biosynergy Pharmaceutical Co., Ltd. (hereinafter referred to as "Biosynergy Pharmaceutical"), as an innovative representative in the domestic biotechnology field, was invited to participate with its core partner, Intellective Bio (Suzhou) Co., Ltd. (hereinafter referred to as "Intellective Bio"). During the meeting, representatives from both companies attended the APEC CEO Summit and listened to a keynote speech by former US President Donald Trump.
This APEC meeting brought together political leaders from Asia-Pacific economies, leaders of leading global companies, and top experts and scholars to conduct in-depth discussions on core topics such as "Technological Innovation Driving Industrial Upgrading" and "Cross-border Cooperation and Resource Integration." Biosynergy Pharmaceutical, with its technological breakthroughs and industrialization practices in the biotechnology field, as well as the efficient cooperative ecosystem built with Intellective Bio, successfully obtained an invitation to the conference, becoming an important participant in the biotechnology sub-sector.
As a key partner of Biosynergy Pharmaceutical, Intellective Bio is a leading CDMO (Contract Development and Manufacturing Organization) in China, possessing core technologies and large-scale production capabilities. Its strengths in drug development, translation, and commercial manufacturing perfectly complement Biosynergy's innovative R&D capabilities. Both companies have long focused on the industrialization of biotechnology achievements, accelerating the process of innovative products moving from the laboratory to the market through technology sharing and process collaboration. Their joint participation in this conference further demonstrates their strong recognition of their collaborative model.
At the APEC CEO Summit, Trump, in his speech, discussed international industrial cooperation and opportunities for manufacturing development, emphasizing the role of cross-economic technology exchange in promoting industrial upgrading. Representatives from Biosynergy and Intellective Bio listened to the speech together, gaining a deeper understanding of "international collaboration accelerating technology transfer" based on their own collaborative experiences, laying the foundation for expanding cross-border cooperation between the two companies.
During the conference, representatives from both companies jointly participated in the "International Cooperation in the Biotechnology Industry" sub-forum, sharing their collaborative experiences with industry partners from across the Asia-Pacific region. Intellective Bio, leveraging its mature CDMO service platform, provided Biosynergy Pharmaceutical with end-to-end support for its innovative R&D, from process development to large-scale production. This collaborative "R&D + production" model has become a typical example of efficient development in the industry. The relevant practices and achievements garnered widespread attention and recognition from the attendees.
Looking ahead, Biosynergy Pharmaceutical will continue to deepen its strategic cooperation with Intellective Bio, fully leveraging the core strengths of both companies in R&D and production. Simultaneously, by utilizing the international exchange platform established by the APEC meeting, they will actively connect with global innovation resources, explore new paths for cross-border technology cooperation and industrial implementation, and inject Chinese momentum into the high-quality development of the biotechnology industry in the Asia-Pacific region.